Halozyme Therapeutics (NASDAQ:HALO) Shares Cross Below Fifty Day Moving Average – What’s Next?

Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) passed below its 50 day moving average during trading on Friday. The stock has a 50 day moving average of $115.19 and traded as low as $102.52. Halozyme Therapeutics shares last traded at $103.63, with a volume of 6,162,578 shares trading hands.

Halozyme Therapeutics News Roundup

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Q3 revenue rose 39% year over year to $493 million and adjusted EPS of $2.39 beat estimates. Record royalty revenue increased 44% to $341 million. Halozyme also raised its 2026 revenue, royalty, EBITDA and adjusted EPS guidance. Q3 results and guidance
• Positive Sentiment: The FDA approved Johnson & Johnson’s RYBREVANT FASPRO, which uses Halozyme’s ENHANZE technology, for certain patients with advanced head and neck cancer. The expanded use could support future royalties. FDA approval
• Positive Sentiment: Halozyme said its analysis of Medicare’s drug-price negotiation rule indicates zero to minimal impact on royalty revenue through at least 2035, easing a potential long-term concern. Medicare rule assessment
• Neutral Sentiment: Citizens JMP raised its price target to $149 and maintained an outperform rating, while Wells Fargo raised its target to $110 but kept an equal-weight rating—signaling differing views on further upside. Citizens JMP rating
• Negative Sentiment: Despite the earnings beat and higher guidance, reports noted a negative share reaction and questions around the guidance reset, suggesting results may not have met elevated investor expectations. The Merck patent dispute also remains an investor focus. Earnings reaction and guidance questions

Wall Street Analyst Weigh In

A number of research analysts recently commented on the stock. Weiss Ratings upgraded shares of Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research note on Monday, August 31st. Zacks Research raised Halozyme Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 13th. Benchmark reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, July 21st. Wall Street Zen lowered shares of Halozyme Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Finally, Stifel Nicolaus set a $130.00 price target on shares of Halozyme Therapeutics in a research note on Friday, October 16th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Halozyme Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $106.09.

Halozyme Therapeutics Price Performance

The company’s 50 day moving average is $115.19 and its 200-day moving average is $84.73. The firm has a market capitalization of $11.76 billion, a price-to-earnings ratio of 26.37, a P/E/G ratio of 0.49 and a beta of 0.92. The company has a current ratio of 2.71, a quick ratio of 2.31 and a debt-to-equity ratio of 13.50.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Thursday, November 5th. The biopharmaceutical company reported $2.39 earnings per share for the quarter, beating analysts’ consensus estimates of $2.30 by $0.09. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The business had revenue of $492.97 million during the quarter, compared to analyst estimates of $491.63 million. During the same period in the previous year, the business earned $1.72 EPS. Halozyme Therapeutics’s revenue was up 39.1% compared to the same quarter last year. Equities research analysts anticipate that Halozyme Therapeutics, Inc. will post 8.32 earnings per share for the current year.

Insider Transactions at Halozyme Therapeutics

In other news, Director Matthew L. Posard sold 18,996 shares of the firm’s stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $107.74, for a total value of $2,046,629.04. Following the transaction, the director directly owned 58,839 shares in the company, valued at $6,339,313.86. This trade represents a 24.41% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $102.80, for a total transaction of $167,152.80. Following the sale, the director owned 40,418 shares in the company, valued at $4,154,970.40. This represents a 3.87% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 125,852 shares of company stock worth $13,538,046 in the last three months. 2.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Halozyme Therapeutics

Several large investors have recently made changes to their positions in HALO. Bank of America Corp DE purchased a new position in Halozyme Therapeutics during the 2nd quarter worth approximately $214,504,000. William Blair Investment Management LLC bought a new stake in shares of Halozyme Therapeutics in the 2nd quarter worth $196,540,000. Jupiter Topco LLC acquired a new stake in shares of Halozyme Therapeutics in the 2nd quarter valued at $105,570,000. Caisse de depot et placement du Quebec bought a new position in Halozyme Therapeutics during the 2nd quarter valued at about $83,940,000. Finally, Congress Asset Management Co. grew its stake in Halozyme Therapeutics by 85.6% in the third quarter. Congress Asset Management Co. now owns 2,281,615 shares of the biopharmaceutical company’s stock valued at $251,890,000 after acquiring an additional 1,052,509 shares during the period. 97.79% of the stock is owned by institutional investors.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that can improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses a proprietary recombinant human hyaluronidase enzyme to facilitate the subcutaneous delivery of biologic drugs and other injectable therapies that may otherwise require intravenous infusion.

Halozyme licenses its technologies to pharmaceutical and biotechnology companies, which use them in a range of marketed and investigational products.